Outcomes
inflammation
INFLAMMATION, SECONDARY
The primary outcome of the trial was the change in CD4+ or CD8+ T-cell counts and CD4/CD8 ratio from enrolment to week 48.The secondary outcomes were the changes in inflammation and other immune characteristics (phenotype of T cells, proportion of cells belonging to different CD4+ and CD8+ T-cell subsets, monocytes, and plasma levels of IL-6) from enrolment to week 48.